Evinacumab reduced LDL cholesterol by a mean of 49% (absolute change of -157 mg/dL) at 4 weeks in adults with homozygous familial hypercholesterolemia.
Does evinacumab reduce LDL cholesterol in adults with homozygous familial hypercholesterolemia?
Evinacumab substantially reduces LDL cholesterol in patients with homozygous familial hypercholesterolemia.
Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.
Gaudet et al. (2017) studied this question. Evinacumab reduced LDL cholesterol by a mean of 49% (absolute change of -157 mg/dL) at 4 weeks in adults with homozygous familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: